Insight 2811 Inc’s iShares Biotechnology ETF IBB Stock Holding History

Insight 2811 Inc’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-930	Closed	-$54K	–	126
2013 Q2	$54K	Buy	+930	New	+$53.8K	0.03%	154

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Insight 2811 Inc's IBB Position: Q3 2013 in Review

Insight 2811 Inc sold out of iShares Biotechnology ETF (IBB) in Q3 2013, closing a stake of 930 shares — an estimated $54K sold.

Insight 2811 Inc first reported a position in IBB in Q2 2013 and held it in 1 quarter. The position peaked at $54K in Q2 2013. 253 funds tracked by Wall St. Rank hold IBB as of Q3 2013.

Insight 2811 Inc reported no remaining iShares Biotechnology ETF position as of Q3 2013 after selling out during the quarter.
Insight 2811 Inc sold 930 iShares Biotechnology ETF shares in Q3 2013, an estimated $54K.
Insight 2811 Inc first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 1 quarter.
Insight 2811 Inc's iShares Biotechnology ETF position peaked at $54K in Q2 2013.
253 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2013.

Based on Insight 2811 Inc's 13F filing for Q3 2013, filed 4 Nov 2013.